Keratoacanthoma - Cheratoacantoma
☆ In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
Tipica Cheratoacantoma (Keratoacanthoma)
References
Keratoacanthoma (KA) hè un tumore di a pelle frequente cunnisciutu per a so crescita rapida è u putenziale di regressu da sè stessu. Hè tipicamenti in l'omi più vechji, di pelle chiara cù una storia di danni da u sole. Mentre a rimozione chirurgica cù l'excisione o a cirugia micrografica di Mohs hè u trattamentu abituale, ci sò parechje altre opzioni di terapia dispunibili.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) hè un tumore di bassa qualità chì principia in certi glanduli in a pelle è s'assumiglia à squamous cell carcinoma (SCC) sottu un microscopiu. Ci hè un dibattitu in corso nantu à se KA deve esse classificatu cum'è una forma di SCC invasive.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) hè u sicondu tipu di cancru più cumuni in e persone, in particulare trà l'anziani. A cirurgia hè tipicamente utilizata per trattà cSCC, ma per certi pazienti chì ùn ponu micca esse cirurgia o sceglienu micca, altre opzioni cum'è trattamenti intralesionali ponu esse cunsiderate. I trattamenti intralesionali tradiziunali (methotrexate or 5-fluorouracil) sò stati utilizati, ma ci hè una ricerca in corso nantu à novi approcci cum'è l'immunoterapia intralesionale è a viroterapia oncolitica. Quì, guardemu diversi trattamenti intralesionali per cSCC, chì varieghja da i metudi classici à e strategie di punta.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Au microscope, le cheratoacantoma (keratoacanthoma) ressemble beaucoup au carcinome épidermoïde. Mentre chì certi patologi classificanu cheratoacantoma (keratoacanthoma) cum'è una entità distinta è micca una malignità, circa 6% di u cheratoacantoma (keratoacanthoma) clinicu è histologicu avanzanu à i cancers squamous invasivi è aggressivi.
○ Diagnosi è Trattamentu
#Dermoscopy
#Skin biopsy